CANC vs. JNJ
CANC (Tema Oncology ETF) is Health & Biotech Equities fund actively managed by Tema, while JNJ (Johnson & Johnson) is a stock. Over the past 3 years, CANC returned 104.11%/yr vs 20.73%/yr for JNJ. At a 0.16 correlation, their price movements are largely independent.
Performance
CANC vs. JNJ - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CANC achieves a 17.91% return, which is significantly lower than JNJ's 25.94% return.
CANC
- 1D
- -1.73%
- 1M
- 9.22%
- 6M
- 13.62%
- YTD
- 17.91%
- 1Y
- 58.70%
- 3Y*
- 104.11%
- 5Y*
- —
- 10Y*
- —
JNJ
- 1D
- 0.31%
- 1M
- 7.02%
- 6M
- 24.28%
- YTD
- 25.94%
- 1Y
- 68.39%
- 3Y*
- 20.73%
- 5Y*
- 11.73%
- 10Y*
- 10.67%
CANC vs. JNJ - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CANC Tema Oncology ETF | 17.91% | 42.92% | -5.37% | 510.51% | -85.34% | -55.35% |
JNJ Johnson & Johnson | 25.94% | 47.48% | -4.81% | -8.58% | 5.97% | 4.98% |
Correlation
The correlation between CANC and JNJ is 0.38, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.38 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Sep 30, 2021 | 0.16 |
Over the past year, CANC and JNJ have become more correlated (0.38) than their long-term average of 0.16, meaning their price movements have been converging.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CANC vs. JNJ — Risk / Return Rank
CANC
JNJ
CANC vs. JNJ - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Tema Oncology ETF (CANC) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CANC | JNJ | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.09 | ||
| Sortino ratioReturn per unit of downside risk | -1.64 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.65 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | 6.34 | 6.27 | +0.07 |
| Martin ratioReturn relative to average drawdown | 17.26 | 18.13 | -0.87 |
Loading charts...
Drawdowns
CANC vs. JNJ - Drawdown Comparison
The maximum CANC drawdown since its inception was -97.53%, which is greater than JNJ's maximum drawdown of -50.67%. Use the drawdown chart below to compare losses from any high point for CANC and JNJ.
Loading charts...
Drawdown Indicators
| CANC | JNJ | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.53% | -50.67% | -46.86% |
Max Drawdown (1Y)Largest decline over 1 year | -9.30% | -10.96% | +1.66% |
Max Drawdown (3Y)Largest decline over 3 years | -30.27% | -15.95% | -14.32% |
Max Drawdown (5Y)Largest decline over 5 years | — | -18.41% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -27.37% | — |
Current DrawdownCurrent decline from peak | -51.12% | -3.54% | -47.58% |
Average DrawdownAverage peak-to-trough decline | -72.70% | -11.89% | -60.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.41% | 3.79% | -0.38% |
Volatility
CANC vs. JNJ - Volatility Comparison
The current volatility for Tema Oncology ETF (CANC) is 6.48%, while Johnson & Johnson (JNJ) has a volatility of 8.87%. This indicates that CANC experiences smaller price fluctuations and is considered to be less risky than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CANC | JNJ | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.48% | 8.87% | -2.39% |
Volatility (6M)Calculated over the trailing 6-month period | 16.50% | 14.29% | +2.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 22.78% | 18.69% | +4.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 277.14% | 17.27% | +259.87% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 277.14% | 18.66% | +258.48% |
Dividends
CANC vs. JNJ - Dividend Comparison
CANC's dividend yield for the trailing twelve months is around 0.05%, less than JNJ's 2.03% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CANC Tema Oncology ETF | 0.05% | 0.06% | 3.00% | 0.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
JNJ Johnson & Johnson | 2.03% | 2.48% | 3.40% | 3.00% | 2.52% | 2.45% | 2.53% | 2.57% | 2.74% | 2.38% | 2.73% | 2.87% |
Frequently Asked Questions
CANC and JNJ have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
JNJ has higher volatility (8.87%) compared to CANC (6.48%). In terms of maximum drawdown, CANC dropped -97.53% vs JNJ's -50.67%.
JNJ currently has the higher Sharpe Ratio (3.68 vs 2.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CANC and JNJ
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer